<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kapil Kumar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Zimetbaum, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term outcomes, such as survival or rate of thromboembolism, are similar with either rhythm or rate control strategies in patients with atrial fibrillation (AF)  (
         <a class="graphic graphic_figure graphicRef61608 graphicRef74434" href="/z/d/graphic/61608.html" rel="external">
          figure 1A-B
         </a>
         ). In addition, anticoagulation is required with both in most patients [
         <a href="#rid1">
          1,2
         </a>
         ]. Thus, the main goal of therapy is to reduce symptoms by decreasing the frequency and duration of episodes [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         When the rhythm control strategy is chosen, the recommended drugs for maintenance of sinus rhythm vary with the clinical setting  (
         <a class="graphic graphic_table graphicRef78424" href="/z/d/graphic/78424.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef83173" href="/z/d/graphic/83173.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3,5
         </a>
         ]. Optimal antiarrhythmic drug therapy should be both effective and have a low incidence of toxicity, including proarrhythmia [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         Most patients for whom rhythm control is chosen will require rate control, both prior to its initiation and after, as many patients will have breakthrough episodes of AF. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
         The studies describing the efficacy and toxicity (including proarrhythmia) of the different antiarrhythmic drugs used to maintain sinus rhythm in patients with AF will be reviewed here. Recommendations concerning the use of pharmacologic therapy, the choice between a rhythm and a rate control strategy, and the role of alternative methods to maintain sinus rhythm in selected patients who are refractory to conventional therapy, including surgery and radiofrequency ablation, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">
          "Atrial fibrillation: Surgical ablation"
         </a>
         .)
        </p>
        <p>
         This topic will also address the issue of whether other medications are associated with a decreased frequency of recurrent AF. (See
         <a class="local">
          'Other therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          META-ANALYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The safety and efficacy of a number of antiarrhythmic drugs was assessed in a 2019 meta-analysis, which included 59 trials (n = 20,981) in which an antiarrhythmic drug for the treatment of atrial fibrillation (AF) was compared against a placebo, another antiarrhythmic, or untreated controls [
         <a href="#rid9">
          9
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compared with controls,
         <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">
          disopyramide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         lowered the recurrence rate of AF (risk ratios [RR] 0.77, 0.83, 0.65, 0.67, 0.52, 0.72, 0.85, and 0.83, respectively).
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         also lowered the risk (RR 0.83).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All-cause mortality was increased (compared with controls) with
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         (2.23, 95% CI 1.03-4.81). Mortality may be increased with other antiarrhythmic drugs, but the evidence was of moderate certainty or weak.
        </p>
        <p>
        </p>
        <p>
         These data support the general observation (as summarized in the following sections) that antiarrhythmics can reduce AF recurrences, but their overall value is limited by adverse effects. All of the antiarrhythmic drugs used to maintain sinus rhythm in AF have the potential to provoke ventricular arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1029.html" rel="external">
          "Sustained monomorphic ventricular tachycardia: Clinical manifestations, diagnosis, and evaluation", section on 'Drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLASS IA ANTIARRHYTHMIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          Quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">
          disopyramide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         are class IA antiarrhythmic drugs  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ). These drugs act by modifying the sodium channel and inhibiting the outward potassium current resulting in QT prolongation. They also have important vagolytic effects. (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          Quinidine
         </a>
         is the most widely studied class IA agent for the maintenance of sinus rhythm in AF [
         <a href="#rid10">
          10,11
         </a>
         ]. Although studies have shown that quinidine can reduce the rate of recurrent AF compared to placebo, it is associated with an increase in mortality, particularly in patients with heart failure [
         <a href="#rid7">
          7,8,12,13
         </a>
         ]. The use of quinidine for the maintenance of sinus rhythm has declined largely because other drugs are both more effective and safer.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">
          Disopyramide
         </a>
         also seems to have some benefit in the prevention of recurrent AF [
         <a href="#rid14">
          14
         </a>
         ], although it must be used with caution since it can significantly worsen underlying heart failure.
        </p>
        <p>
         The efficacy of oral
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         has been evaluated in older and poorly controlled trials or in patients who recently underwent coronary artery bypass surgery [
         <a href="#rid15">
          15-17
         </a>
         ]. Oral procainamide is not readily available in the US.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLASS IC ANTIARRHYTHMIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          Flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         are classified as class IC antiarrhythmic agents, although they are known to have significantly different electrophysiologic and other properties. The following observations have been made regarding their efficacy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compared to placebo, both are more effective in maintaining sinus rhythm at six months and in prolonging the time to atrial fibrillation (AF) recurrence [
         <a href="#rid18">
          18-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          Flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         appear to have equal efficacy [
         <a href="#rid27">
          27,28
         </a>
         ]. In a randomized, open-label study of 200 patients, for example, the probability of a safe and effective response (maintenance of sinus rhythm or fewer episodes of paroxysmal AF) at one year was 77 and 75 percent with flecainide and propafenone, respectively [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis evaluated trials of patients with AF resistant to class I drugs or
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         who were treated with
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         or
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         after cardioversion [
         <a href="#rid29">
          29
         </a>
         ]. Maintenance of sinus rhythm at 12 months was significantly more likely with amiodarone (60 versus 34 percent with flecainide).
        </p>
        <p>
        </p>
        <p>
         Despite the apparent benefit for the prevention of recurrent AF, the toxicity associated with these drugs has restricted their use. The cardiac complications of the class IC drugs include worsening of heart failure, bradycardia, and presumably drug-induced atrial and ventricular arrhythmias in 7 to 27 percent of cases. In up to 13 percent of patients AF recurs as, or converts to, persistent atrial flutter [
         <a href="#rid30">
          30
         </a>
         ]. Radiofrequency ablation of the atrial flutter, with continuation of the antiarrhythmic agent, is an effective approach for reducing arrhythmia recurrence and duration [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="local">
          'Hybrid therapy in patients who develop atrial flutter'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">
          "Atrial flutter: Maintenance of sinus rhythm"
         </a>
         .)
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         is restricted to those patients who have no structural heart disease, particularly coronary heart disease. The concern about the use of the class IC agents is primarily the result of the Cardiac Arrhythmia Suppression Trial (CAST), which showed that flecainide increased the number of deaths among patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction  (
         <a class="graphic graphic_figure graphicRef59975" href="/z/d/graphic/59975.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]. It is not known if these findings can be extrapolated to other types of heart disease. (See
         <a class="medical medical_review" href="/z/d/html/917.html" rel="external">
          "Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management", section on 'Class I agents'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          Propafenone
         </a>
         has some mild beta-blocking activity in addition to its effects on the sodium channel. Thus, its toxicity may not be identical to that of
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         and, in patients with ventricular arrhythmia, propafenone appears to be less proarrhythmic. In a study of 480 patients with supraventricular arrhythmia treated with propafenone for 14 months, 59 percent of patients experienced at least one side effect; the drug was discontinued due to an adverse reaction in only 15 percent, while 17 percent required a reduction in dose [
         <a href="#rid33">
          33
         </a>
         ]. Arrhythmia aggravation occurred in 2 percent of patients; the incidence was higher in those with structural heart disease compared to those without (3 versus 1 percent).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLASS III ANTIARRHYTHMIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         are classified as class III antiarrhythmic agents. There are, however, many dissimilarities among these drugs, and they should be considered separately. (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Amiodarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is the most effective antiarrhythmic drug for the prevention of atrial fibrillation (AF), as demonstrated in the following randomized trials [
         <a href="#rid34">
          34-39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Canadian Trial of Atrial Fibrillation (CTAF) randomly assigned 403 patients who had at least one episode of AF within six months of entry to low-dose
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. After a mean follow-up of 16 months, amiodarone was associated with a significantly greater likelihood of being free from recurrent AF (65 versus 37 percent for sotalol and propafenone) and a longer median time to recurrence (&gt;468 versus 98 days)  (
         <a class="graphic graphic_figure graphicRef69285" href="/z/d/graphic/69285.html" rel="external">
          figure 3
         </a>
         ). There was no difference among the three therapies in mortality, but there was an almost significant trend toward an increased incidence of side effects resulting in drug discontinuation with amiodarone (18 versus 11 percent for sotalol or propafenone). (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar relative efficacies were noted in a substudy from the AFFIRM trial [
         <a href="#rid37">
          37
         </a>
         ]. Patients in the rhythm control arm were randomly assigned to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         (256 patients), amiodarone or a class I drug (222 patients), or sotalol and a class I drug (183 patients). The one-year endpoint was defined as the patient being alive, being in sinus rhythm at follow-up visits, still taking the drug (ie, no discontinuation for episodes of highly symptomatic AF), and needing no electrical or pharmacologic cardioversions. The likelihood of achieving the endpoint was significantly higher with amiodarone compared to sotalol (60 versus 38 percent) or a class I drug (62 versus 23 percent). In comparison to CTAF, amiodarone was not associated with a higher risk than sotalol of cessation of therapy for adverse effects (13 versus 16 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The SAFE-T trial compared
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , and placebo in patients with persistent AF for both conversion to sinus rhythm and maintenance of sinus rhythm [
         <a href="#rid35">
          35
         </a>
         ]. The rate of maintenance of sinus rhythm was significantly higher at one year with amiodarone than sotalol or placebo and with sotalol than placebo (52 versus 32 and 13 percent on intention to treat analysis and 65 versus 40 and 18 percent on treatment received analysis). The primary endpoint, the median time to recurrence beginning after day 28, was 487, 74, and 6 days in the three groups. However, among the approximately 25 percent of patients with ischemic heart disease, the median time to recurrence with amiodarone was not significantly different from sotalol (569 versus 428 days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There was no difference among the study groups in terms of adverse effects except for a small increase in minor bleeding among patients treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . The mortality rate was not significantly higher with amiodarone and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         combined compared to placebo (4.36 versus 2.84 per 100 person-years), but trials of patients with heart failure or myocardial infarction have not shown an increase in mortality with amiodarone [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nonrandomized studies of patients with chronic or paroxysmal AF refractory to most other antiarrhythmic agents have shown that
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         maintained sinus rhythm in 53 to 79 percent of cases during a 15 to 27 month follow-up [
         <a href="#rid42">
          42-45
         </a>
         ]. Amiodarone is less effective in patients who have AF for over one year or who have an enlarged LA. However, even in this group, the success rate with amiodarone may be as high as 50 to 60 percent [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has also been evaluated as a prophylactic therapy to prevent AF after cardiac surgery. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Sotalol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is not very effective in converting AF to sinus rhythm, but is useful in preventing recurrent episodes [
         <a href="#rid46">
          46-48
         </a>
         ]. As an example, one study randomly assigned 253 patients with AF or atrial flutter to placebo or three doses of sotalol (80, 120, or 160 mg BID); the recurrence rate at one year was 72, 70, 60, and 55 percent, respectively, and the median times to recurrence were 27, 106, 119, and 175 days, respectively [
         <a href="#rid48">
          48
         </a>
         ]. As noted with other drugs, predictors of AF recurrence were the presence of coronary disease, duration of AF &gt;2 months before reversion, LA size &gt;60 mm, and older age.
        </p>
        <p>
         A number of studies have compared the efficacy of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         to other antiarrhythmic drugs for preventing recurrent AF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As noted above, randomized controlled trials and a substudy analysis from AFFIRM demonstrated that
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         was less effective than
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid34">
          34-37
         </a>
         ]. After a mean follow-up of 16 months in CTAF, for example, amiodarone was associated with a significantly greater likelihood of being free from recurrent AF (65 versus 37 percent for sotalol and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ) and a longer median time to recurrence (&gt;468 versus 98 days)  (
         <a class="graphic graphic_figure graphicRef69285" href="/z/d/graphic/69285.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. Similar findings were noted in SAFE-T [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Amiodarone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         appears to have equal efficacy to
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         [
         <a href="#rid34">
          34,49,50
         </a>
         ]. The best data come from CTAF, which randomly assigned 403 patients who had at least one episode of AF within six months of entry to low-dose
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , sotalol, or propafenone [
         <a href="#rid34">
          34
         </a>
         ]. After a mean follow-up of 16 months, the proportion of patients free from recurrent AF was 37 percent with both sotalol and propafenone  (
         <a class="graphic graphic_figure graphicRef69285" href="/z/d/graphic/69285.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="local">
          'Amiodarone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Dofetilide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         is a class III antiarrhythmic drug  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ). The SAFIRE-D trial evaluated 204 patients with AF who were successfully cardioverted electrically or pharmacologically with dofetilide and maintained on a dose of 125, 250, or 500 µg twice daily or placebo [
         <a href="#rid51">
          51
         </a>
         ]. The probability of remaining in sinus rhythm at one year was significantly greater for dofetilide compared to placebo (40, 37, and 58 versus 25 percent). The all-cause mortality was the same in the four groups. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Specific antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
         The results were similar in the EMERALD trial, which randomly assigned patients who were pharmacologically or electrically cardioverted to therapy with one of three doses of
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         (125, 250, or 500 µg twice daily),
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         (80 mg twice daily), or placebo [
         <a href="#rid52">
          52
         </a>
         ]. After 12 months of therapy, AF recurred in 79 percent of placebo patients, 34 percent of those receiving the highest dose of dofetilide, and between 48 and 60 percent in the other groups. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide"
         </a>
         .)
        </p>
        <p>
         It is of concern that nonfatal torsades de pointes (TdP) or sudden death occurred in four patients in the high-dose
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         group [
         <a href="#rid52">
          52
         </a>
         ]. However, a pooled analysis of 1346 patients receiving dofetilide and 677 treated with placebo in randomized clinical trials of the treatment of supraventricular arrhythmias found that dofetilide was not associated with an increase in mortality (adjusted hazard ratio 1.1) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The lack of an increase in mortality with
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         is reassuring. However, because drug-induced TdP is relatively rare and can be treated if it occurs in a monitored setting, the impact of this complication may not be seen in analyses limited to overall survival. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Dronedarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          Dronedarone
         </a>
         is a derivative of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . In patients with AF, randomized trials with up to 12 months of follow-up have found that dronedarone prevents recurrent AF and was safe (including no increased risk of serious arrhythmias) [
         <a href="#rid54">
          54-56
         </a>
         ]. However, in the ANDROMEDA trial in patients with advanced heart failure from LV systolic dysfunction, there was an increased risk of death with dronedarone and the trial was stopped early [
         <a href="#rid57">
          57
         </a>
         ]. As a result, dronedarone is contraindicated in this population of patients. (See
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure", section on 'Antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
         In the ATHENA trial 4628 patients with AF were randomly assigned to either
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         or placebo [
         <a href="#rid58">
          58
         </a>
         ]. Patients with New York Heart Association (NYHA) class II or III heart failure comprised 21 percent of the study population, but patients with NYHA class IV heart failure were excluded. After a mean follow-up period of 21 months, dronedarone significantly reduced the primary outcome of death or cardiovascular hospitalization (31.9 versus 39.4 percent, hazard ratio 0.76, 95% CI 0.69-0.84) and the secondary outcome of cardiovascular death (2.7 versus 3.9 percent, hazard ratio 0.71, 95% CI 0.51-0.98). Dronedarone is the only antiarrhythmic drug that has shown a salutary effect on mortality. Maintenance of sinus rhythm was not one of the endpoints in ATHENA.
        </p>
        <p>
         The DIONYSOS study was a short-term (median duration of seven months) comparison between
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         to assess the differences in drug tolerability and AF recurrence in 504 patients [
         <a href="#rid59">
          59
         </a>
         ]. Sixty percent of the patients had persistent AF. The authors found that the composite primary endpoint of AF recurrence or premature study drug discontinuation occurred in 75.5 percent of patients taking dronedarone, but only 58.8 percent of patients taking amiodarone. This endpoint was primarily driven by AF recurrence on dronedarone compared to amiodarone (63.5 versus 42.0 percent, respectively). Drug discontinuation and the main safety endpoints of extra-cardiac toxicity only tended to be less with dronedarone, but did not reach statistical significance. It is possibly that with longer follow-up periods there would have been a greater difference in noncardiac side effects, since the toxicity with amiodarone is typically manifest after several months to years of use.
        </p>
        <p>
         In a meta-analysis of
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         trials prior to the DIONYSOS study, where the effect of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         versus dronedarone was estimated with the use of indirect comparison and normal logistic meta-analysis models, a similar conclusion was reached [
         <a href="#rid60">
          60
         </a>
         ]. Amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events.
        </p>
        <p>
         The PALLAS trial, which was stopped early due to an increase in adverse events in patients taking
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         , evaluated the potential use of dronedarone to improve cardiovascular outcomes in patients with permanent AF. This trial is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations", section on 'Concerns about dronedarone'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Ibutilide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         is only available for intravenous use and therefore is useful for the acute reversion of AF, not for long-term prevention [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13502785">
         <span class="h2">
          Vernakalant
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          Vernakalant
         </a>
         is considered a relatively “atrially-selective” antiarrhythmic agent since one of its main actions is to inhibit the ultrarapid potassium current (IKur) and the acetylcholine potassium current (IKAch), both of which are predominantly found in the atria. Vernakalant also mildly inhibits other potassium channels and, to a much lesser extent, the sodium current. The program for vernakalant drug development in the US has been terminated. The drug is available in an intravenous form to terminate AF in Europe.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          BETA BLOCKERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no evidence to support the use of beta blockers (aside for
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ), in the absence of other antiarrhythmic drugs, for the prevention of atrial fibrillation (AF). In patients with heart failure (HF) due to systolic dysfunction, chronic treatment with certain beta blockers reduces mortality. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'
         </a>
         .)
        </p>
        <p>
         There is evidence that beta blockers may also reduce the likelihood of the development of AF in patients with HF. A systematic review including seven randomized trials of 11,952 patients evaluated the efficacy of beta blockers for this purpose [
         <a href="#rid62">
          62
         </a>
         ]. Among patients who were in sinus rhythm at baseline and were followed for six months to two years, the incidence of new onset AF was significantly lower in patients treated with beta blockers than those assigned to placebo (28 versus 39 per 1000 patient years). (See
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure"
         </a>
         .)
        </p>
        <p>
         A separate issue is whether beta blockers, which are felt to have some antiarrhythmic properties  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ), are effective for preventing recurrent atrial fibrillation in patients with no heart disease. The evidence to support their use for this purpose is scant, and any reduction in the reported frequency of AF may be attributable to improved rate control that may render recurrent AF silent.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          VERAPAMIL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The calcium channel blocking agents
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         impair conduction and prolong refractoriness in the AV node. They have been used both acutely and chronically to slow the ventricular response in atrial fibrillation (AF).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         has also been investigated for its effectiveness in maintaining sinus rhythm after cardioversion. The rationale for this approach is the observation that the electrical remodeling that occurs during AF is thought to be due, at least in part, to abnormal calcium loading during rapid atrial rates. In studies in animals and humans, verapamil has been shown to prevent electrical remodeling [
         <a href="#rid63">
          63,64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16402.html" rel="external">
          "Mechanisms of atrial fibrillation", section on 'Electrical remodeling'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         as a single agent was not effective in preventing AF recurrence in the VERDICT trial, in which 97 patients with persistent AF were randomly assigned to either verapamil or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ]. There was no difference in AF recurrence rates at one month. It was suggested that verapamil may be effective only when given with a sodium or potassium channel blocking agent [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Verapamil with another agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon the observations cited above, several studies evaluated the benefit of
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         with another agent in preventing recurrences of AF. In the small VEPARAF trial, the addition of verapamil to either
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         significantly reduced the incidence of recurrent AF within three months of cardioversion compared with either agent alone [
         <a href="#rid67">
          67
         </a>
         ]. The larger PAFAC and SOPAT trials found the combination of verapamil and
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         to be comparable to
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , and superior to placebo, in preventing AF recurrence.
        </p>
        <p>
         In PAFAC, 848 patients with persistent AF were cardioverted and then randomly assigned to
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , or placebo [
         <a href="#rid68">
          68
         </a>
         ]. Patients used an event recorder to record and transmit at least one ECG daily during a mean of nine months of follow-up. The incidence of death or any AF recurrence was significantly lower for both sotalol and for quinidine plus verapamil than for placebo (67 and 65 versus 83 percent). Serious adverse events were not more common with quinidine plus verapamil than with sotalol, and the only episodes of torsades de pointes occurred with sotalol.
        </p>
        <p>
         In the SOPAT trial, 1033 patients with recurrent symptomatic paroxysmal AF were randomly assigned to placebo,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , or one of two dose combinations of
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid69">
          69
         </a>
         ]. As in the PAFAC trial, patients recorded and transmitted at least one ECG daily with an event recorder. The mean time to first AF recurrence was prolonged significantly in all three active treatment groups compared to placebo. At a mean of eight months of follow-up, the number of days of symptomatic AF was reduced significantly for all three active treatment arms compared to placebo. There was no difference between the sotalol and the two quinidine plus verapamil treatment groups in either of these efficacy endpoints or in the incidence of serious adverse side effects.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to conventional antiarrhythmic drugs, a number of other agents have been investigated for the purpose of suppressing atrial fibrillation (AF).
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          ACE inhibitors, angiotensin II receptor blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) reduce the incidence of atrial fibrillation in selected patient populations. In a recent meta-analysis of 26 randomized trials that evaluated the effect of ACE inhibitors and ARBs on the prevention of AF, it was demonstrated that both classes of drugs had a similar beneficial effect on AF [
         <a href="#rid70">
          70
         </a>
         ]. The effect was more potent for recurrent AF compared to primary prevention of AF (OR 0.45 versus 0.80, respectively). ACE inhibitor or ARB effect on AF was additive to that of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         when used concurrently and endured even in patients with depressive LV function. This issue is discussed in further detail separately. (See
         <a class="medical medical_review" href="/z/d/html/935.html" rel="external">
          "ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Magnesium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although not a primary antiarrhythmic agent, magnesium affects atrial electrophysiologic properties. Some studies, particularly those in patients undergoing coronary artery bypass surgery, have found that magnesium deficiency is associated with AF and that magnesium supplementation reduces its incidence. (See
         <a class="medical medical_review" href="/z/d/html/846.html" rel="external">
          "Significance of hypomagnesemia in cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Ineffective or possibly effective therapies'
         </a>
         .)
        </p>
        <p>
         The role of oral magnesium therapy in the prevention of recurrent AF after cardioversion was evaluated in one study of 301 patients who were followed for at least six months after the restoration of sinus rhythm; magnesium therapy alone or in combination with
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         was
         <strong>
          ineffective
         </strong>
         for preventing recurrent AF [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Statins
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is some evidence that statins may prevent recurrences in patients with lone AF [
         <a href="#rid72">
          72,73
         </a>
         ], ischemic heart disease [
         <a href="#rid73">
          73,74
         </a>
         ] and after cardiac bypass surgery [
         <a href="#rid73">
          73,75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Aldosterone Blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         These drugs have been useful in the treatment of heart failure.
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         and
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         have effects on atrial electrophysiologic properties in experimental animals, but no studies in patients with AF have been done.
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          DRUG-REFRACTORY ATRIAL FIBRILLATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention. There are limited data to support the use of combination antiarrhythmic drug therapy, and this approach may expose the patient to a greater risk of proarrhythmia and other side effects. As a result, combination therapy is not recommended.
        </p>
        <p>
         Such patients can be treated with a rate control strategy or referred for nonpharmacologic therapy of atrial fibrillation (AF). These options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiofrequency catheter ablation (RFA), which is the most common of these approaches. (See
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgical procedures such as the maze operation, particularly for patients undergoing cardiac surgery for another indication. Some centers also offer “mini-maze” operations using limited bilateral thoracotomies as standalone procedures as well. (See
         <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">
          "Atrial fibrillation: Surgical ablation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          HYBRID THERAPY IN PATIENTS WHO DEVELOP ATRIAL FLUTTER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial flutter can occur after the initiation of antiarrhythmic drug therapy in patients with atrial fibrillation (AF), especially with the use of class IC agents or
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . One approach to managing this situation has been a “hybrid approach” that involves ablation of atrial flutter by creating a block across the cavotricuspid isthmus and then continuation of the antiarrhythmic drug. Although this approach may be helpful in maintaining sinus rhythm in the short term, data (articles below) suggest that in the long term, there is a high recurrence of AF [
         <a href="#rid76">
          76,77
         </a>
         ]. Therefore, the development of atrial flutter on an antiarrhythmic drug may be considered failure of therapy.
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for the use drug therapy to maintain sinus rhythm in patients with atrial fibrillation (AF) are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p>
         The following are the important points made in this topic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main goal of drug therapy to maintain sinus rhythm is to reduce symptoms by decreasing the frequency and duration of episodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary endpoint of many clinical trials involving antiarrhythmic drugs has been time to first recurrence of AF. However, there is great variation in efficacy of antiarrhythmic drugs from patient to patient. Although a drug may be shown to significantly prolong the time to recurrence of AF in a clinical trial, some patients will experience no benefit and others will experience a dramatic reduction in AF frequency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other outcomes are also important. These include the effect of the drug on overall AF burden, AF episode duration, symptoms, ventricular rate control, and hospitalizations. A single recurrence of AF on a drug does not necessarily indicate treatment failure or require a change in therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the rhythm control strategy is chosen, the recommended drugs for maintenance of sinus rhythm vary with the clinical setting  (
         <a class="graphic graphic_table graphicRef78424" href="/z/d/graphic/78424.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef83173" href="/z/d/graphic/83173.html" rel="external">
          algorithm 1
         </a>
         ). Optimal antiarrhythmic drug therapy should be both effective and have a low incidence of toxicity, including proarrhythmia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         are effective in the maintenance of sinus rhythm. Of these, amiodarone is the most effective, but is associated with the development of more frequent side effects. Dronedarone is also associated with the development of significant side effects as well as worse outcomes in some groups of patients with AF. (See
         <a class="local">
          'Amiodarone'
         </a>
         above and
         <a class="local">
          'Dronedarone'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ. Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. Am Heart J 2000; 139:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valembois L, Audureau E, Takeda A, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2019; 9:CD005049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Södermark T, Jonsson B, Olsson A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J 1975; 37:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984; 65:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimold SC, Chalmers TC, Berlin JA, Antman EM. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. Am Heart J 1992; 124:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlson BW, Torstensson I, Abjörn C, et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szekely P, Sideris DA, Batson GA. Maintenance of sinus rhythm after atrial defibrillation. Br Heart J 1970; 32:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madrid AH, Moro C, Marín-Huerta E, et al. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993; 14:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg 1992; 26:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation 1995; 92:2550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 79:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller JC, Geller M, Carlson MD, Waldo AL. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol 2001; 87:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meinertz T, Lip GY, Lombardi F, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett EL, Page RL, Carlson M, et al. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chimienti M, Cullen MT Jr, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996; 77:60A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996; 77:66A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999; 83:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nabar A, Rodriguez LM, Timmermans C, et al. Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation. Am J Cardiol 1999; 83:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000; 84:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorian P, Mangat I. Restoring sinus rhythm in atrial fibrillation: a Pyrrhic victory? J Am Coll Cardiol 2003; 42:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodsky MA, Allen BJ, Walker CJ 3rd, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoularigis J, Röthlisberger C, Skudicky D, et al. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 1993; 72:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallik DM, Kim SG, Ferrick KJ, et al. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997; 134:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alt E, Ammer R, Lehmann G, et al. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 1997; 134:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999; 84:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001; 88:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson JJ. Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 1999; 99:2486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 1999; 138:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003; 24:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005; 23:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001; 12:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight BP. Calcium channel blockade for prevention of recurrent atrial fibrillation: have we reached a VERDICT? J Cardiovasc Electrophysiol 2001; 12:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Simone A, De Pasquale M, De Matteis C, et al. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J 2004; 25:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frick M, Darpö B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000; 21:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García Seara J, Raposeiras Roubin S, Gude Sampedro F, et al. Failure of hybrid therapy for the prevention of long-term recurrence of atrial fibrillation. Int J Cardiol 2014; 176:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anastasio N, Frankel DS, Deyell MW, et al. Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation. J Interv Card Electrophysiol 2012; 35:57.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1038 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466506" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A comparison of rate control and rhythm control in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466507" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287978" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10783204" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Appropriate outcome measures in trials evaluating treatment of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21177058" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678922" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2144796" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1512329" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31483500" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1093559" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6367096" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1388328" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2437788" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3289932" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5212345" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Maintenance of sinus rhythm after atrial defibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404944" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparison of flecainide and procainamide in cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287833" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2511744" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2513143" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2001087" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586356" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052343" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2303641" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11152834" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480038" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14556870" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607393" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607394" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7677555" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080423" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080440" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1900101" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8752188" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738049" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872201" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amiodarone versus sotalol for atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10956284" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849654" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849655" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Restoring sinus rhythm in atrial fibrillation: a Pyrrhic victory?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17329700" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Amiodarone for atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9371164" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659722" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3630939" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3942054" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Amiodarone for refractory atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4067122" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352186" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313591" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9327697" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10496434" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8438741" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11564387" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11067793" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10330376" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10539835" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effect of dofetilide on survival in patients with supraventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12919771" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dronedarone for prevention of atrial fibrillation: a dose-ranging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16252015" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804843" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565860" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Increased mortality after dronedarone therapy for severe heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19213680" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effect of dronedarone on cardiovascular events in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20384650" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19744618" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8840852" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17289748" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9107184" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Verapamil reduces tachycardia-induced electrical remodeling of the atria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9315545" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11469424" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11469425" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Calcium channel blockade for prevention of recurrent atrial fibrillation: have we reached a VERDICT?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12909071" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302102" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15321697" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20811347" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924301" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14636918" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18294568" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14675569" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074212" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25043211" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Failure of hybrid therapy for the prevention of long-term recurrence of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22552760" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
